488 related articles for article (PubMed ID: 23560506)
1. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
5. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
6. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Cvetković RS; Perry CM
Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for chronic lymphocytic leukemia.
Robak T
Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
11. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
12. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
13. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Lin TS; Blum KA; Fischer DB; Mitchell SM; Ruppert AS; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Johnson AJ; Schaaf LJ; Grever MR; Byrd JC
J Clin Oncol; 2010 Jan; 28(3):418-23. PubMed ID: 20008633
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
